Navigation Links
genae Appoints Chief Medical Officer
Date:4/16/2012

ANTWERP, Belgium, April 16, 2012 /PRNewswire/ --

genae, a leading Contract Research Organization (CRO) and services provider for the medical device industries, today announced that Catalina Trana, MD, has been appointed Chief Medical Officer. In this role, Dr. Trana will be responsible for all clinical, safety and risk management related to genae's research services.

"I am delighted to welcome Catalina, whose extensive clinical and research expertise will be of great benefit to the many aspects of our services offering," said Bart Segers, Chairman and CEO of genae. "We believe that her experience as an interventional cardiologist provides her with a unique opportunity to view our services with an unsurpassed balance of clinical insight, business acumen and regulatory and safety compliance.

Dr. Trana holds the position of Cardiology Specialist at the Interventional Cardiology Department of the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. She was a fellow at the Cardiovascular Center Aalst, OLVZ, Aalst, Belgium and worked and trained at the Interventional Cardiology Department and Cardiovascular Surgical Department of the Cardiovascular Center in Iasi, Romania; and at the Catholic University of Leuven, Belgium. Her scientific and research work is illustrated by peer-reviewed publications and presentations during international congresses and symposia.

About genae

genae is a full service CRO and an innovative services provider for the medical industries and aims at improving health and quality of life by innovating and accelerating high quality research. The group is ISO 9001 certified for Clinical Trial Management, Core Laboratory Services and Additional Services for the Medical Industries.

genae associates nv is a privately held company with principal offices in Antwerp, Belgium.

genae Americas Inc. is a privately held company with principal offices in Cleveland, OH.

Please visit: http://www.genae.com

Company Contact

genae associates nv
Justitiestraat 6B
2018 Antwerp, Belgium
Aly Talen, RN
Sr. VP Business Development
+32-3-290-03-06
aly.talen@genae.com

genae Americas Inc.
Global Cardiovascular Innovation Center
10000 Cedar Avenue
Cleveland, OH 44106, USA
Dimitri Buytaert, PT CCRA
President
+1-216-445-4535
dimitri.buytaert@genae.com


'/>"/>
SOURCE genae associates nv
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
2. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
3. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
4. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
6. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
7. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
8. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
11. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):